Uk Biobank is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
UK Biobank is a large-scale biomedical database and research resource containing detailed genetic and health information from approximately 500,000 volunteer participants across [1]
the United Kingdom.[2] The study represents one of the most comprehensive population-based cohorts globally and has become invaluable for [3]
researching neurodegenerative diseases.[1:1] [4]
UK Biobank recruited 502,536 participants aged 40-69 years between 2006-2010 from across the United Kingdom.[3:1] Participants provided detailed questionnaires, physical measures, and biological samples. [5]
UK Biobank is conducting brain imaging on 100,000 participants using: [6:1]
UK Biobank has generated whole exome sequencing (WES) data for all participants and whole genome sequencing (WGS) for approximately 200,000 participants.[13] [7:1]
All participants were genotyped using custom arrays, enabling: [8:1]
UK Biobank has been instrumental in: [9:1]
The cohort has enabled: [10:1]
UK Biobank data have been used to study: [11:1]
UK Biobank has identified hundreds of genetic variants associated with neurological traits, revealing new biological pathways involved in neurodegeneration.[26] [12:1]
The study has established relationships between modifiable factors (sleep, exercise, diet) and neurodegenerative disease risk.[27] [13:1]
Imaging data have revealed patterns of brain aging and their genetic and environmental determinants.[28] [14:1]
UK Biobank enables identification of blood-based biomarkers for early detection of neurodegeneration.[29] [15:1]
UK Biobank is open to approved researchers worldwide. Access is provided through an application process with data available in a secure research environment.[30] [16:1]
UK Biobank has transformed neurodegeneration research by: [17:1]
The study of Uk Biobank has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [18:1]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [19:1]
Additional evidence sources: [20:1] [21:1] [22:1] [23:1] [24:1] [25:1] [26:1] [27:1] [28:1] [29:1] [30:1] [31:1] [32:1] [33:1] [34:1]
Bycroft C, et al. The UK Biobank resource with deep phenotyping and genomic data. 2018. ↩︎ ↩︎
Sudlow C, et al. UK Biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age. 2015. ↩︎
Littlejohns TJ, et al. The UK Biobank: Selection, representativeness and a baseline for neurodegenerative disease research. 2019. ↩︎ ↩︎
Elliott LT, et al. Genome-wide association studies in UK Biobank. 2019. ↩︎ ↩︎
Miller KL, et al. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. 2016. ↩︎ ↩︎
Fry A, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. 2017. ↩︎ ↩︎
Alfaro-Almagro F, et al. Image processing and Quality Control for the first 10,000 brain imaging datasets from UK Biobank. 2018. ↩︎ ↩︎
Miller KL, et al. Functional imaging in population neuroscience. 2019. ↩︎ ↩︎
Tournier JD, et al. Diffusion MRI in UK Biobank. 2019. ↩︎ ↩︎
UK Biobank Protocol. Chapter 7: Health outcomes. 2024. 2024. ↩︎ ↩︎
Backman JD, et al. Exome sequencing and genetic diversity. 2021. ↩︎ ↩︎
GWAS Catalog. UK Biobank publications. Nat Genet. 2024. 2024. ↩︎ ↩︎
Choi SW, et al. Tutorial: A guide to performing polygenic risk score analyses. 2020. ↩︎ ↩︎
Smith GD, et al. Mendelian randomization: Genetic supports for causal inference. 2016. ↩︎ ↩︎
Wightman DP, et al. GWAS meta-analysis of Alzheimer's Disease. 2021. ↩︎ ↩︎
Livingston G, et al. Dementia prevention, intervention, and care. 2020. ↩︎ ↩︎
Nalls MA, et al. Identification of novel risk loci for Parkinson's Disease. 2019. ↩︎ ↩︎
Hutter C, et al. Genetic architecture of Parkinson's Disease in the UK Biobank. 2020. ↩︎ ↩︎
Schrag A, et al. Prodromal Parkinson's Disease in UK Biobank. 2020. ↩︎ ↩︎
Al-Chalabi A, et al. ALS genetics and environment. 2023. ↩︎ ↩︎
International Multiple Sclerosis Genetics Consortium. MS genetic architecture. Nat Genet. 2023;55(11):1783-1798. 2023. ↩︎ ↩︎
Chen MH, et al. Neurological traits in UK Biobank. 2023. ↩︎ ↩︎
Dhana K, et al. Healthy lifestyle and life expectancy. 2022. ↩︎ ↩︎
Henriksen K, et al. Blood biomarkers in UK Biobank. 2022. ↩︎ ↩︎
UK Biobank Access Procedures and Data Showcase. 2024. 2024. ↩︎ ↩︎
Glahn DC, et al. Integrative approaches to understanding brain disorders. 2020. ↩︎ ↩︎
Lambert JC, et al. Meta-analysis of Alzheimer's Disease genetic studies. 2023. ↩︎ ↩︎
International Neuroinformatics Coordinating Facility. UK Biobank collaboration. 2024.## See Also. 2024. ↩︎ ↩︎